| 摘要: |
| 目的：分析匹多莫德口服液对支原体肺炎（MPP）患儿综合免疫状态的改善作用。方法：将180例支原体肺炎患儿随机分为对照组和观察组各90例，对照组采用阿奇霉素10 mg/(kg·d)等常规基础治疗，观察组加用匹多莫德口服液每次10 mL，2次/天。采取免疫速率散射比浊法测定患儿的血清免疫球蛋白和补体水平，取流式细胞术检测患儿的T细胞亚群变化。结果：观察组患儿发烧、咳嗽、肺部啰音等临床症状消失时间和白细胞计数、C反应蛋白水平恢复正常时间均显示低于对照组，观察组治疗总有效率为93.33%，显著高于对照组的81.11%（P<0.05）。治疗7 d、14 d后，观察组患儿IgA、IgG水平显著高于对照组，而IgE和补体C3、C4水平则显著低于对照组；CD3+、CD4+水平和CD4+/CD8+显著高于对照组，CD8+水平则显著低于对照组（P<0.05）。结论：匹多莫德能有效改善MPP患儿的综合免疫状态，有利于患儿的康复。 |
| 关键词: 支原体肺炎 匹多莫德 免疫状态 |
| DOI：doi:10.13407/j.cnki.jpp.1672-108X.2016.02.011 |
|
| 基金项目: |
|
| Observe the Effect of Oral Pidotimod on Comprehensive Immune Status for Children with Mycoplasma Pneumonia |
| Wang Zubin1, Lin Jie2, Luo Yongfu1 |
| (1. Songci People’ Hospital of Hubei Province, Hubei Songci 434200, China; 2. Songci Traditional Chinese Medical Hospital of Hubei Province, Hubei Songci 434200, China) |
| Abstract: |
| Objective: To analysis the effect of oral pidotimod on comprehensive immune status for children with mycoplasma pneumonia. Methods: 180 cases of children with mycoplasma pneumonia were randomly divided into two groups, control group and observation group, each group had 90 cases, children in control group were treated with azithromycin (10 mg·kg-1·d-1) as basic treatment, those in observation group were combined with oral pidotimod (10 mL/time, 2 times/day). Then the difference of efficacy between the two groups were compared, and the serum levels of immunoglobulins and complement, T cell subsets of two groups were detected by immunization rate nephelometry and flow cytometry, and compared before and after treatment. Results: The disappearance times of clinical symptoms such as fever, cough, pulmonary rales, etc and the recovery time of white blood cell count, C-reactive protein levels of observation group were all shorter than control group, total effective rate of observation group was 93.33% which was significantly higher than control group’s 81.11% (P<0.05). After 7, 14 days of treatment, the serum levels of IgA, IgG of observation group were higher than control group, while the IgE and complement C3, C4 were lower than control group, the levels of CD3+, CD4+ and CD4+/CD8+ significantly were higher than control group, the levels of CD8+ was lower than control group (all P<0.05). Conclusion: Oral pidotimod can effectively improve the comprehensive immune status for children with mycoplasma pneumonia, and conducive to the rehabilitation of children. |
| Key words: Mycoplasma pneumonia Pidotimod Immune status |
